April 30, 2014
Hisamitsu Pharmaceutical announced on April 24 that it has started a PI clinical trial of its investigational transdermal schizophrenia treatment HP-3070 in the US. The company’s US subsidiary Noven Pharmaceuticals Inc. is to conduct the study in schizophrenia patients to...read more